Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

The value of phase 4 clinical testing.

Vlahakes GJ.

N Engl J Med. 2006 Jan 26;354(4):413-5. No abstract available.

PMID:
16436775
2.

Aprotinin revisited.

Deanda A Jr, Spiess BD.

J Thorac Cardiovasc Surg. 2012 Nov;144(5):998-1002. doi: 10.1016/j.jtcvs.2012.06.035. Epub 2012 Jul 15. Review.

3.

Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery.

Ide M, Bolliger D, Taketomi T, Tanaka KA.

J Anesth. 2010 Feb;24(1):96-106. doi: 10.1007/s00540-009-0866-9. Epub 2009 Dec 29. Review.

PMID:
20039075
4.

Antifibrinolytics in major orthopaedic surgery.

Eubanks JD.

J Am Acad Orthop Surg. 2010 Mar;18(3):132-8. Review.

PMID:
20190103
5.

Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials.

Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T.

Interact Cardiovasc Thorac Surg. 2009 Jul;9(1):98-101. doi: 10.1510/icvts.2008.198325. Epub 2009 Apr 20. Review.

6.

Hemostatic drugs.

Mannucci PM.

N Engl J Med. 1998 Jul 23;339(4):245-53. Review. No abstract available.

PMID:
9673304
7.

Benefits and risks of aprotinin use during cardiac surgery.

Kristeller JL, Roslund BP, Stahl RF.

Pharmacotherapy. 2008 Jan;28(1):112-24. Review.

PMID:
18154481
8.

Current antifibrinolytic therapy for coronary artery revascularization.

Trudell J, McMurdy N.

AANA J. 2008 Apr;76(2):121-4. Review.

PMID:
18478817
9.

Mortality manifesto: a meta-analysis of aprotinin and tranexamic acid mortality.

Brown JR.

Eur J Cardiothorac Surg. 2009 Oct;36(4):781-2. doi: 10.1016/j.ejcts.2009.06.014. Epub 2009 Jul 18. Review. No abstract available.

PMID:
19616962
10.

Aprotinin: 1 year on.

Dietrich W.

Curr Opin Anaesthesiol. 2009 Feb;22(1):121-7. doi: 10.1097/ACO.0b013e32831c833f. Review.

PMID:
19295302
11.

Managing fibrinolysis without aprotinin.

Edmunds LH Jr.

Ann Thorac Surg. 2010 Jan;89(1):324-31. doi: 10.1016/j.athoracsur.2009.10.043. Review.

PMID:
20103278
12.

Safety aspects of aprotinin therapy in cardiac surgery patients.

Royston D, Chhatwani A.

Expert Opin Drug Saf. 2006 Jul;5(4):539-52. Review.

PMID:
16774492
13.

[Hemostatic management for cardiac surgical patients in the post-aprotinin era].

Tanaka K.

Masui. 2009 Mar;58(3):288-97. Review. Japanese.

PMID:
19306629
14.

Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?

Zufferey P, Merquiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, Samama CM, Molliex S.

Anesthesiology. 2006 Nov;105(5):1034-46. Review.

PMID:
17065899
15.

[Aprotinin in the control of surgical hemorrhage].

Rocha E, Antonio Páramo J, Hermida J.

Med Clin (Barc). 1996 Mar 2;106(8):307-16. Review. Spanish. No abstract available.

PMID:
8667690
16.

Aspects of bleeding after cardiac surgery in children.

McEwan A.

Paediatr Anaesth. 2007 Dec;17(12):1126-33. Review. No abstract available.

PMID:
17986030
17.

Current status of non-transfusional haemostatic agents.

Cattaneo M, Mannucci PM.

Haematologica. 1999 Jun;84 Suppl EHA-4:120-3. Review. No abstract available.

PMID:
10907488
18.

Clinical application of inhibitors of fibrinolysis.

Verstraete M.

Drugs. 1985 Mar;29(3):236-61. Review.

PMID:
2580684
19.

Antifibrinolytics.

Schmarts.

Acta Anaesthesiol Belg. 2003;54(4):319-22. Review. No abstract available.

PMID:
14719353
20.

Reduction in requirements for allogeneic blood products: pharmacologic methods.

Janssens M, Hartstein G, David JL.

Ann Thorac Surg. 1996 Dec;62(6):1944-50. Review.

PMID:
8957438
Items per page

Supplemental Content

Write to the Help Desk